Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.


TSX:DHT.UN - Post by User

User Avatar Image
(64)
•••
  • SONOFFERGUSX
Comment by SONOFFERGUSon Aug 29, 2024 5:41pm
98 Views
Post# 36201977

RE:RE:RE:NCIB

RE:RE:RE:NCIBIf I have the right numbers, there is a ton of room on the NCIB -- the limiting factor is the automatic unit purchase plan.  

20-Nov-23  3,280,195 units authorized under NCIB

Q4/23  0
Q1/24  0
Q2/24 207,600
Q3/24 198,746 (to ER date per Q2 MDnA)

That leaves a whopping 2,873,849 units. Daily limit 14,784, so remaining annual limit is not a constraint absent block trades (of which I've noticed zero).

I have to imagine that today's 3% drawndown caught Gary's attention and that buybacks (through a new AUPP or otherwise) will kick in tomorrow.

The underlying value of DHT is clear -- as supported by the analysts' buy recos and PTs -- and it will be a shame if they let shorts shake out a bunch of retail by not protecting the unit price when it's trading so far below NBV (let alone NPV).  

Good luck to all who play!





<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities